An international panel of patients, physicians and researchers has agreed upon evidence-based target glycemic ranges for people who use continuous glucose monitors (CGMs) to control their diabetes.
Announced today at the American Diabetes Association (ADA) conference in San Francisco, the International Consensus on Time-in-Range (TIR) was based on data from large pre-CGM clinical trials, CGM randomized controlled trials and expert opinion. It outlines recommended cut points that the panel agreed individuals with type 1 diabetes, type 2 diabetes and women with diabetes during pregnancy should strive to achieve.
In spite of CGMs’ increased accuracy and convenience, the devices’ use remains low in clinical settings, possibly due in part to the lack of official glycemic target ranges, the ADA said in a statement. The 43-member panel also strongly recommended creating a standard CGM report similar to the ambulatory glucose profile (AGP Report) to translate these new CGM targets into clinical practice.
